Financials Laboratoires Euromedis

Equities

Market Closed - Euronext Paris Other stock markets 05:40:15 2024-04-26 am EDT			5-day change	1st Jan Change
4.64 ^EUR	0.00%		+0.22%	-12.78%

2023	Euromedis Groupe Reports Earnings Results for the Half Year Ended June 30, 2023	CI
2023	Euromedis Groupe Reports Earnings Results for the Full Year Ended December 31, 2022	CI

Fiscal Period: December	2018	2019	2020	2021	2022	2023	2024	2025
Capitalization ¹	18.16	12.47	37.64	31.27	14.38	12.94	12.94	-
Enterprise Value (EV) ¹	18.16	27.47	21.9	-0.587	0.4192	-8.064	-9.164	-10.46
P/E ratio	-	-3.57 x	1.8 x	16.7 x	-2.44 x	18.6 x	11.3 x	10.8 x
Yield	-	-	-	-	-	-	-	-
Capitalization / Revenue	0.17 x	0.16 x	0.19 x	0.28 x	0.27 x	0.21 x	0.2 x	0.19 x
EV / Revenue	0.17 x	0.36 x	0.11 x	-0.01 x	0.01 x	-0.13 x	-0.14 x	-0.16 x
EV / EBITDA	-7.89 x	-687 x	0.65 x	-0.09 x	-0.06 x	-3.84 x	-3.16 x	-3.38 x
EV / FCF	-	-	-	-	-	-1.19 x	-7.64 x	-8.05 x
FCF Yield	-	-	-	-	-	-84.3%	-13.1%	-12.4%
Price to Book	-	-	-	-	-	0.39 x	0.38 x	0.36 x
Nbr of stocks (in thousands)	2,751	2,747	2,747	2,978	2,990	2,788	2,788	-
Reference price ²	6.600	4.540	13.70	10.50	4.810	4.640	4.640	4.640
Announcement Date	4/25/19	4/22/20	4/23/21	4/22/22	4/28/23	-	-	-

¹EUR in Million²EUR

Estimates

Fiscal Period: December	2018	2019	2020	2021	2022	2023	2024	2025
Net sales ¹	108	77.08	193.4	111.9	54.18	60.6	63.8	67
EBITDA ¹	-2.3	-0.04	33.5	6.4	-6.9	2.1	2.9	3.1
EBIT ¹	-	-	-	-	-	1.1	1.9	2
Operating Margin	-	-	-	-	-	1.82%	2.98%	2.99%
Earnings before Tax (EBT)	-	-	-	-	-	-	-	-
Net income ¹	-6.9	-3.8	22.7	2.3	-5.933	0.9	1.5	1.5
Net margin	-6.39%	-4.93%	11.74%	2.06%	-10.95%	1.49%	2.35%	2.24%
EPS ²	-	-1.270	7.610	0.6300	-1.970	0.2500	0.4100	0.4300
Free Cash Flow ¹	-	-	-	-	-	6.8	1.2	1.3
FCF margin	-	-	-	-	-	11.22%	1.88%	1.94%
FCF Conversion (EBITDA)	-	-	-	-	-	323.81%	41.38%	41.94%
FCF Conversion (Net income)	-	-	-	-	-	755.56%	80%	86.67%
Dividend per Share	-	-	-	-	-	-	-	-
Announcement Date	4/25/19	4/22/20	4/23/21	4/22/22	4/28/23	-	-	-

¹EUR in Million²EUR

Estimates

Fiscal Period: December	2018	2019	2020	2021	2022	2023	2024	2025
Net Debt ¹	-	15	-	-	-	-	-	-
Net Cash position ¹	-	-	15.7	31.9	14	21	22.1	23.4
Leverage (Debt/EBITDA)	-	-375 x	-	-	-	-	-	-
Free Cash Flow ¹	-	-	-	-	-	6.8	1.2	1.3
ROE (net income / shareholders' equity)	-	-19.5%	83.2%	5.7%	-15.7%	2.5%	4%	4%
ROA (Net income/ Total Assets)	-	-	-	-	-	-	-	-
Assets ¹	-	-	-	-	-	-	-	-
Book Value Per Share ²	-	-	-	-	-	11.80	12.30	12.80
Cash Flow per Share ²	-	0.3200	4.310	5.370	-0.3500	0.5000	0.6800	0.7100
Capex ¹	1.95	-	-	-	-	0.7	0.8	0.8
Capex / Sales	1.81%	-	-	-	-	1.16%	1.25%	1.19%
Announcement Date	4/25/19	4/22/20	4/23/21	4/22/22	4/28/23	-	-	-

¹EUR in Million²EUR

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

4.64 EUR

Average target price

4 EUR

Spread / Average Target

-13.79%

	1st Jan change	Capi.
LABORATOIRES EUROMEDIS	-12.78%	13.81M
ABBOTT LABORATORIES	-2.31%	187B
MEDTRONIC PLC	-3.20%	106B
BECTON, DICKINSON AND COMPANY	-5.04%	66.9B
DEXCOM, INC.	+0.20%	49.45B
CENCORA, INC.	+17.29%	48B
HOYA CORPORATION	+4.06%	40.84B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.48B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.25B
TERUMO CORPORATION	+12.96%	24.62B